Tekmira Pharmaceuticals will supply one of its experimental Ebola treatments for clinical studies to be conducted in West Africa.» Read More
CNBC's Dominic Chu takes a look at the big movers in biotech on Wednesday.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.
Washington needs to stop trying to force companies to stay in the US and address the real problem, says Edward J. Reilly of FTI Consulting.
Allergan on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.
States may be on the hook for $55 billion to pay for hepatitis C treatments like Sovaldi, a new study says.
Novartis and Google have agreed to develop "smart" contact lenses to help diabetics track blood glucose levels or restore the eye's ability to focus.
The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.
Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
Former star trader Raj Mahal breaks down what really goes on in a trader's brain, from being a pint-sized hustler to winning big at the casino.
Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.
People are turning themselves into cyborgs by embedding magnets and computer chips directly into their bodies, NBC News reports.
CNBC's Meg Tirrell reports on how the pharmaceutical industry is dealing with the Alzheimer's epidemic.
Data from a study of Sarepta Therapeutics' experimental drug for Duchenne muscular dystrophy suggest it helped slow declines in walking ability for almost three years.
Narcotics prosecutors say a NYC hospital's former pharmacy chief stole nearly 200,000 oxycodone pills over more than five years.
An unconventional but effective treatment against a deadly superbug is raising worries about a possible black market.
Certain areas of the brain have shown links to trading behavior and success, according to new research published Monday.
The largest U.S. pharmacy benefit manager, Express Scripts, is cutting back on compounded medications, saying most are ineffective or overpriced.
Massachusetts is expected to add almost 400 jobs in biotech manufacturing by 2016. CNBC's Mary Thompson reports Quincy College aims to fill some of those jobs with a new program.
Get the best of CNBC in your inbox